Glycogenic hepatopathy

From WikiMD's WELLNESSPEDIA

(Redirected from Mauriac syndrome)


Glycogenic hepatopathy
Synonyms
Pronounce N/A
Specialty N/A
Symptoms Hepatomegaly, abdominal pain, nausea, vomiting
Complications Liver dysfunction
Onset
Duration
Types
Causes Diabetes mellitus, especially Type 1 diabetes
Risks Poor glycemic control
Diagnosis Liver biopsy, imaging studies
Differential diagnosis Non-alcoholic fatty liver disease, hepatitis
Prevention Good glycemic control
Treatment Insulin therapy, dietary management
Medication
Prognosis Generally good with treatment
Frequency Rare
Deaths


Glycogenic hepatopathy is a rare and underdiagnosed complication of Type 1 diabetes, characterized by the excessive accumulation of glycogen in the hepatocytes. It was first described in 1930 by Mauriac as a component of Mauriac syndrome, a rare pediatric syndrome associated with poorly controlled type 1 diabetes.

Etiology[edit]

The exact cause of glycogenic hepatopathy is not well understood. It is believed to be related to poor glycemic control in patients with type 1 diabetes. The condition is thought to result from the rapid fluctuation of blood glucose levels, leading to excessive glycogen storage in the hepatocytes.

Clinical Presentation[edit]

Patients with glycogenic hepatopathy typically present with hepatomegaly, elevated liver enzymes, and poorly controlled diabetes. The condition is often mistaken for nonalcoholic fatty liver disease (NAFLD), as the clinical presentation and laboratory findings can be similar. However, unlike NAFLD, glycogenic hepatopathy is reversible with improved glycemic control.

Diagnosis[edit]

The diagnosis of glycogenic hepatopathy is typically made through a combination of clinical history, laboratory findings, and liver biopsy. The liver biopsy will show swollen hepatocytes filled with glycogen, without the inflammation or fibrosis typically seen in NAFLD.

Treatment[edit]

The primary treatment for glycogenic hepatopathy is improved glycemic control. This can be achieved through a combination of diet, exercise, and medication. In severe cases, insulin therapy may be required. With improved glycemic control, the hepatomegaly and liver enzyme elevations typically resolve within weeks to months.

Prognosis[edit]

The prognosis for glycogenic hepatopathy is generally good, with most patients experiencing complete resolution of symptoms with improved glycemic control. However, if left untreated, the condition can lead to severe liver damage and potentially liver failure.

See Also[edit]


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.